PMID- 18458987
OWN - NLM
STAT- MEDLINE
DCOM- 20090730
LR  - 20211020
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Linking)
VI  - 19
IP  - 12
DP  - 2008 Dec
TI  - Outcomes after switching from one bisphosphonate to another in 146 patients at a 
      single university hospital.
PG  - 1777-83
LID - 10.1007/s00198-008-0618-y [doi]
AB  - Most patients who switched to a second bisphosphonate continued their treatment 
      long term, although those who stopped their first drug because of adverse events 
      were likely to discontinue the second drug for the same reason. Switching to 
      another bisphosphonate is a reasonable treatment option for some patients with 
      treatment failure. INTRODUCTION: Patients who experience treatment failure with a 
      bisphosphonate because of adverse events (AEs) or other reasons might receive a 
      second bisphosphonate. However, the frequency and benefits of switching 
      bisphosphonates are unknown. METHODS: We retrospectively evaluated 197 men and 
      1110 women newly treated with bisphosphonates between 1 January 2000 and 30 June 
      2005 at our university hospital. RESULTS: Among the 497 patients who discontinued 
      bisphosphonate treatment, 146 were switched to a second bisphosphonate. The 
      cumulative probabilities of persistence of treatment after 3 years were 45% with 
      the first bisphosphonate and 65% with the second (P = 0.017). Age >or=65 years, 
      switching bisphosphonates because of AEs, and male gender were associated (P < 
      0.05) with low persistence of treatment with the second bisphosphonate. 
      Discontinuation of the first drug because of AEs was associated with an increased 
      rate of discontinuation of the second drug because of AEs (hazard ratio, 4.2; 95% 
      confidence interval, 2.1-8.4). CONCLUSIONS: Patients who switched bisphosphonates 
      had high rates of persistence of therapy. Those who stopped their first 
      bisphosphonate because of AEs were at risk of discontinuing the second drug for 
      the same reason. Switching to another bisphosphonate is a reasonable treatment 
      option for some patients with treatment failure.
FAU - Ideguchi, H
AU  - Ideguchi H
AD  - Center for Rheumatic Diseases, Yokohama City University Medical Center, 
      Minami-ku, Yokohama, Kanagawa 232-0024, Japan.
FAU - Ohno, S
AU  - Ohno S
FAU - Takase, K
AU  - Takase K
FAU - Ueda, A
AU  - Ueda A
FAU - Ishigatsubo, Y
AU  - Ishigatsubo Y
LA  - eng
PT  - Journal Article
DEP - 20080506
PL  - England
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation 
      between the European Foundation for Osteoporosis and the National Osteoporosis 
      Foundation of the USA
JID - 9100105
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Density Conservation Agents/adverse effects/*therapeutic use
MH  - Diphosphonates/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Osteoporosis/*drug therapy
MH  - Patient Compliance/statistics & numerical data
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2008/05/07 09:00
MHDA- 2009/07/31 09:00
CRDT- 2008/05/07 09:00
PHST- 2007/10/20 00:00 [received]
PHST- 2008/03/10 00:00 [accepted]
PHST- 2008/05/07 09:00 [pubmed]
PHST- 2009/07/31 09:00 [medline]
PHST- 2008/05/07 09:00 [entrez]
AID - 10.1007/s00198-008-0618-y [doi]
PST - ppublish
SO  - Osteoporos Int. 2008 Dec;19(12):1777-83. doi: 10.1007/s00198-008-0618-y. Epub 
      2008 May 6.